Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.
new at shorting SO hold or cover????? Haven't covered yet but not as green as i was when it was in low $24's BUT PT raised to $40 https://www.marketbeat.com/stocks/N...m_source=GeneralSocialMedia&utm_medium=Social
Insmed Announces Proposed Public Offering of Common Stock https://finance.yahoo.com/news/insmed-announces-proposed-public-offering-200100282.html
^^ holding up better than i expected/wanted! Got scared when it started heading north after post question more so for myself yesterday and ended up covering for $1.03 profit rather than $2+ profit. Should have played it up BUT up too much for my comfort level so patiently waiting/watching for another short which should be coming up with offering (i think?)
Insmed Announces Pricing of Public Offering of Common Stock BRIDGEWATER, N.J., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (INSM) announced today that it priced an offering of 12,281,000 shares of its common stock in a registered underwritten public offering at a price of $28.50 per share before underwriting discounts and commissions. All of the shares of common stock in the offering are to be sold by Insmed. Gross proceeds from this offering before deducting underwriting discounts and commissions are expected to be approximately $350.0 million. Insmed has granted the underwriters a 30-day option to purchase up to an additional 1,842,150 shares of its common stock at the offering price, less underwriting discounts and commissions.... https://finance.yahoo.com/news/insmed-announces-pricing-public-offering-013715984.html
Volume way low today. Really wanted to short @ $30+ but don't wanna hold over weekend but it hasta come back down sooner or later!
8K today + couple Form 4 sells last week and waiting/watching for more lol! https://www.sec.gov/cgi-bin/browse-...001104506&type=&dateb=&owner=include&count=40 Back to add latest PR - Insmed Announces Closing of Public Offering - https://finance.yahoo.com/news/insmed-announces-closing-public-offering-200100479.html
$INSM data release sparked a revaluation of the company, tutes want a piece of this no matter what, don't be on the wrong side of the trade
